A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

TumorAdenocarcinoma

Interventions

DRUG

Pembrolizumab

Given by IV

DRUG

lenvatinib

Given by PO

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

STRATEGIC ALLIANCE: Merck

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER